+34 679 490 537info@nanbiosis.com

News

nanbiosis news

Carlos Rodriguez-Abreu (NANBIOSIS U12) keynote speaker in OKINAWA COLLOIDS 2019


Carlos Rodriguez-Abreu, Scientific Director of NANBIOSIS U12 Nanostructured liquid characterization unit has been invited speaker at OKINAWA COLLOIDS 2019 conference in Okinawa, Japan on November 3 to 8, 2019 in the session Foams / Bubbles / Emulsions and Microemulsions.
Foams and emulsions stabilized by surfactants, amphiphilic polymers and solid particles are essential formulations for developing pharmaceuticals, cosmetics, foods and so on. Recently, many functional systems have been proposed including stimuli responsive materials, biocompatible materials, and environmental affinity materials. The topics of this session include a wide range of subjects: physical properties, phase behaviors and new functions of these systems.

Read More

NANBIOSIS internal dissemination day

NANBIOSIS has celebrated today the second edition of NANBIOSIS internal dissemination day, at the ICMAB-CSIC, Barcelona.

The Day has been focuss on the staff that deals with the day-to-day work of the units, especially technical staff. The event was attended by technicians and coordinators of the units of Catalonia and Aragon (almost 30 face-to-face assistants) and has been followed through the streaming broadcast by the other units.

The day has been presented by the NANBIOSIS Scientific Director Jaume Veciana and the Nerea Argárate Coordinator, followed by a round of presentations by the attendees and their work in the different NANBIOSIS units.

The first part has focused on the Cutting Edge Biomedical Solutions as integral solutions to the problems that arise in biomedical research integrating the expertise of several units presented by Nerea Argarate, as well as several presentations from the units of the Minima invasion Surgery Center Jesus Usón de Cáceres CCMIJU by Javier García, Jorge Bote and Verónica Crisóstomo focused on potential internal collaborations, synergies and complementarities in NANBIOSIS between the CIBER, CCMIJU and Bionand units.

Javier García Casado CCMIJU

The second part dealt with the implementation of quality systems, the NANBIOSIS coordinator has presented the NANBIOSIS Quality Plan and Arnau Jaumandreu (NANBIOSIS Unit 6 Technician) has made a good summary of the steps to follow in the implementation of a quality system with recommendations from its experience in the process followed by unit 6, all followed by a debate.

Arnau Jaumandreu

In the last part Anna May Masnou (Head of Communication and Dissemination of ICMAB-CSIC) has spoken about the use of the NANBIOSIS brand and communication channels, the dissemination of science and its returns. The day has ended with a space for debate.

Anna May Masnou ICMAB-CSIC
Read More

NANBIOSIS in the NEW BOOK of the UNIQUE SCIENTIFIC AND TECHNICAL INFRASTRUCTURES (ICTS)

We are pleased to inform that the new book of Unique Scientific and Technical Infrastructures (ICTS) has been published by the Spanish Ministery of Innovation, Science and Universities with the collaborations of the ICTS.

The Spanish Map of Unique Scientific and Technical Infrastructures (ICTS), goups biomedical technologies, cleanrooms, supercomputers, advanced lasers, telescopes, underground laboratories, synchrotrons, particle accelerators, biological reserves, solar, oceanic and hydraulic platforms, oceanographic research ships, and polar bases in Antarctica. A total of 29 ICTS, made up of 62 nodes, allow for ambitious research projects that attract first-rate talent and enhance the technological and innovative industry capacities.

“Through a one-stop system, NANBIOSIS provides comprehensive solutions that are tailored to the challenges thaat researchers face in biomedicine… its configuration means pioneering multidisciplinary studies can be conducted. Some examples are outlined below.”

NANBIOSIS ICTS

Among these examples, several results combining the expertise of several Units of NANBIOSIS: an original method to prepare smaller nanoparticles of polylactic-co-glycolic acid (PLGA) functionalised with cell-penetrating peptides (CPP), which penetrate the cell membrane and release controlled drug doses into the cells; an innovative medication administration system based on emerging bionanotechnology with protein nanoparticles that selectively deliver lead the therapeutic agent to the tumour cells or a bioactive surgical mesh, covered with adult stem cells, to reduce the inflammatory process associated with implanting this type of material that proved a beneficial effect on the biocompatibility in animal models.

As Pedro Duque, Spanish Minister of Innovation, Science and Universities says in its prelude “The Unique Scientific and Technical Infrastructures described in this book are crucial for Spain and its science, technology, and innovation. I encourage you to browse the pages of this book and discover the state-of-the-art infrastructures that represent the scientific and technological capacity that exists in Spain today. You won’t regret it

Read More

I ONLINE Course on Introduction to Quality Management in Laboratories in the Biosanitary Field

The Jesús Usón Minimally Invasive Surgery Center (JUMISC), organizes the 1st ONLINE Course on Introduction to Quality Management in Laboratories in the Biosanitary Field.

The course will count with the expertise Beatriz Moreno Lobato, Scientific Director of NANBIOSIS Unit 19 CLINICAL TEST LAB, among others.

The Course is directed to middle-level technicians: Auxiliary Care of Nursing and Pharmacy and Parapharmacy and also to higher degree technicians: Pathological and Cytodiagnostic Anatomy, Oral Hygiene, Image for Diagnosis and Nuclear Medicine, Clinical and Biomedical Laboratory, Dental Prosthetics, Dietary

The course has a capacity for forty attendees and registration is now open here:

The course program consists of:
Thematic Unit 1: Quality Management Systems (7.5h) (15h student dedication)

  • Historical justification and principles of quality management (1,5h) (J Sánchez)
  • Quality Assurance Systems (J Sánchez)
  • ISO 9001 (1,5h) (J Sánchez)
  • ISO 17025 Standard (1,5h) (J Sánchez)
  • BPL regulations (1,5h) (J Fco Guillén)
  • Quality Philosophy. New strategies (1,5h) (J Sánchez)

Thematic Unit 2: Quality in the field of the laboratory (8.5h) (17h student dedication)

  • Generalities and Management in a Clinical Analysis Laboratory (2h) (B Moreno)
  • Safety standards in laboratories (2h) (J Boat)
  • Quality in other laboratories in the biomedical field (4,5h) (N Hernández / J García / N Picado)

Thematic Unit 3: Analytical Quality (4h) (8h student dedication)

  • Definition of analytical quality. General aspects (B Moreno)
  • Analytical tests (B Moreno)
  • Management and conservation of samples. Analytical Interferences (B Moreno)
  • Validation of analytical methods (B Moreno)
  • Calibration and equipment management. Quality and PNT manuals (J Fco Guillén / B Moreno)

Thematic Unit 4: Introduction to GLP (4h) (8h student dedication)

  • Regulation and relationship with other standards (J Fco Guillén)
  • ISO 13485 and other related standards (J Fco Guillén)
  • Documentation and Quality Assurance (J Fco Guillén)
  • BPL applications (B Moreno)

Final exam and Satisfaction Survey (2h)

Read More

Understanding between doctors and engineers: essential to advance in health

Pablo Laguna Lasaosa, New Director of I3A and scientific director of NANBIOSIS U27 High Performance Computing talks about Biomedical Engineering in the radio programm “La Brujula de Aragón” @OndaCero_

Professor of signal and communications, expert of biomedical signals in the cardio vascular domain, Pablo Laguna talks about engineering today and how the relative weight of engineering is nowadays repesented by the information engineering, computer engineering and the treatment of information to be applyed in different domains, new materials and new ways of addressing and solving problems.

For the recently appointed director of the I3A, there is an opportunity in this updated concept of enineering to try to attract the female sector. “In the I3A -says Pablo Laguna- there are a good number of female engineers, pioneer women, of recognized national and international prestige, who make the effort of diffusion so that other women are encouraged to continue their way”.

Doctor Laguna also explains the I3A research which groups forty or fifty research groups in four work domains:

Chemical engineering, what is known as processes and recycling, (recycling, sludge management or new chemical processes to obtain new materials …), with a very close relationship with the recycling industry.

More classic industrial technologies, the mechanical part, where the great chanllenges are in knowledge, in simulations… to give value to companies.

Information and telecommunications technologies, which brings together the technologies of communication, computer science, data management and artificial intelligence.

Engineering applied to the resolution of biological problems, diagnosis of diseases, therapy … interdisciplinarity and understanding between the doctor and the engineer are nowadays essential to advance in the field of health.

To follow the interview in spanish: from min 13:15
https://www.ondacero.es/emisoras/aragon/audios-podcast/brujula/la-brujula-de-aragon-12112019_201911125dcb01af0cf235944927d27e.html

Read More

Pablo Laguna, new director of the Aragon Engineering Research Institute

Pablo Laguna Lasaosa, Scientific Director of Unit 27 High Performance Computing has been elected new director of the Aragon Engineering Research Institute (I3A).

Pablo Laguna Lasaosa, Professor of Signal Theory and Communications at the School of Engineering and Architecture (EINA) of the University of Zaragoza, develops its research activity in the field of signal processing, particularly applied to biomedical applications. Laguna is co-author of more than 150 research articles on this subject, more than 10 book chapters, more than 300 international conference documents and director of 15 doctoral theses. He has led a good number of projects on the interpretation of biomedical signals, especially in the cardiovascular domain, most of them with international collaborations with clinical centers, academia and engineering companies.
 
Proff Laguna holds some international scientific responsibilities as a member (2008-2019) and president (2015-2018) of the board of directors of the Computing in Cardiology conference, as editor of the Digital Signal Processing (Eurasip) and Medical and Biological Engineering (Springer), In addition to organizing different scientific conferences. Select member (fellow) of the Institute of Electrical and Electronics Engineers (IEEE), of the European Alliance for Medical and Biological Engineering & Science (EAMBES) and of the International Academy of Medical and Biological Engineering (IAMBE). He is co-author, together with Dr. L. Sörnmo, of the book Bioelectrical Signal Processing in Cardiac and Neurological Applications (Elsevier, 2005), considered a reference in his field.
 
Within the field of university management and research, Professor Laguna has been a member of I3A since its inception, deputy director of International Relations of EINA (1999-2002), principal investigator of the Biomedical Signal Interpretation and Computational Simulation (BSICoS) group of the I3A, coordinator of the Biomedical Engineering division of the I3A (2000-2011) and its deputy director, responsible for the Master in Biomedical Engineering (2003-2010) and of the Doctoral Program in Biomedical Engineering of the I3A since its creation in 2002 until the present. He has also been the scientific director of the Network Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine CIBER-BBN (2011-2015), where he is still a member.
 
His work program as director of the I3A over the next four years will focus on this important institute of the University of Zaragoza advancing as a reference structure for quality research, multidisciplinary and with a vocation to transfer its results to society.

Read More

III Conference on the Disclosure of Biomedical and Experimental Sciences

The III Conference for the Disclosure of Biomedical and Experimental Sciences will take place at the Center for Minimally Invasive Surgery Jesús Usón of Cáceres, on December 5, 2019. It will be attended by Francisco Miguel Sanchez Margallo, Deputy Scientific Director of NANBIOSIS and Beatriz Moreno Lobato, Scientific Director of Unit 19 of NANBIOSIS

FREE ACTIVITY – Requires prior registration until full capacity is reached

Pre- registration: https://www.ccmijesususon.com/formacion/preinscripcion/1173/

Program:

Read More

Jesús Santamaría new Corresponding Academician of the Royal Canary Academy of Sciences

Jesús Marcos Santamaría Ramiro, Scientific Director of NANBIOSIS Unit 9 Synthesis of Nanoparticles Professor of Chemical Engineering at the University of Zaragoza and Deputy Director of the University Institute of Nanoscience of Aragon has been appointed new Corresponding Academician of the Royal Canary Academy of Sciences.

Reception of the new Corresponding Academician took place last November 7th at the Hall of the Canary Islands Advisory Council in La Laguna the entry speech of the new Corresponding Academician was tittled “Heterogeneous Catalysis 4.0: Opportunities for catalysts when they leave the reactor”



Read More

Non-Hodgkin lymphoma treatment with protein nanoparticles

A study result of collaboration between researchers of two NANBIOSIS units managed to produce a potent antitumor effect in an animal model with non-Hodgkin lymphoma

A non-Hodgkin’s lymphoma, NHL is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system.
Lymphoma. NHL is a term that’s used for many different types of lymphoma that share some characteristics.  The most prevalent type of non-Hodgkin lymphoma is called diffuse large B-cell lymphoma (LDCGB). Although there are treatments for this pathology, there are non-responders.

This nanoparticle can be developed as a nanopharmaceutical, in order to introduce a new treatment, which could be used in 40 percent of patients with non-Hodgkin lymphoma who do not respond to current therapy, and avoiding the adverse effects associated with conventional treatment.

The research conducted by the CIBER-BBN at the Hospital de Sant Pau, led by Ramón Mangues (Nanbiosis U18 Nanotoxicology Unit) and the Autonomous University of Barcelona, led by Antoni Villaverde Nanbiosis U1 Protein Production Platform (PPP) has demonstrated the high selectivity of a protein-based nanomedicine and created by the researchers themselves, for the targeted delivery of a toxin in the tumor cells to induce their selective death. The objective is that these nanoparticles can be developed as a nanopharmaceutical, which could be used in 40 percent of patients with non-Hodgkin lymphoma who do not respond to current therapy, avoiding the adverse effects associated with conventional treatment

This selective effect of the nanopharmaceutical is due to the specific interaction between a targeting peptide that contains the protein nanoparticle that carries the toxin and the CXCR4 cell receptor that is highly overexpressed in lymphoma cells. This is the first time that the uptake of protein nanoparticles in different organs of a hematological neoplasm is quantified.

This observation has shown that 86 percent of the administered dose accumulates in cancer cells, a substantial improvement compared to other non-protein nanoparticles or other drug targeting systems such as drug-antibody conjugates, which only reach 1 percent of the dose in the tumor.

As Ramón Mangues, Scientific Director of Nanbiosis U18 Nanotoxicology Unit, explains, “the new protein nanoparticle contains a ligand that identifies a CXCR4 receptor on the surface of cancer cells in which it enters selectively, reaching a very high uptake of the tumor and very low in the rest of the body, which greatly exceeds the tumor uptake of drugs used for this type of lymphoma.”

The bioluminescent follow-up of cancer cells and nanoparticle biodistribution and toxicity studies has been performed in the ICTS NANBIOSIS Nanotoxicology Unit Protein production has been partially performed by the ICTS “NANBIOSIS”, more specifically by the Unit of Protein Production Platform.

Read More

NANBIOSIS expertise on Nanoparticles Characterization by Amable Bernabé.

Amable Bernabé, Technical Coordinator of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit has given a course from Monday, 7 October, to Wednesday, 9 October on “Characterization techniques for particulate materials”. The course has counted with 12 participants from different CSIC centers (including ICMAB, IBM-CNM, ICM, IQAC…) and has introduced the participants to different techniques to characterize nanoparticles and other particulate matter, including the basic fundamentals, sample preparation, practical examples and results interpretation. 

It is the second time that Amable Bernabé, technician from the Sof tLab, has decided to offer this course to all the CSIC community, so they can learn new methods to characterize nanoparticles, the theory behind the techniques, and how to manage the equipment.

Specifically, the techniques shown are:

Theory:

  • Dynamic Light Scattering (DLS) with Zetasizer Nano ZS (Malvern Instruments)
    • Size distribution
    • Z Potential 
  • Nanoparticle Tracking Analysis (NTA) with Nanosight NS300 (Malvern Instruments)
    • Size distribution
    • Particle concentration
    • Fluorescence
  • Light Scattering (LS) with Mastersizer 2000 (Malvern Instruments)
    • Size distribution

Practice:

  • Sample analysis and practical cases of Dynamic Light Scattering with the Zetasizer Nano ZS (Malvern Instruments) equipment.
  • Samples analysis and practical cases of the Nanoparticle Tracking Analysis (NTA) technique with the Nanosight NS300 (Malvern Instruments) equipment.
  • Sample analysis and practical cases of the Light Scattering (LS) technique with the Mastersizer 2000 (Malvern Instruments) instrument. 
Read More